Sera Prognostics (NASDAQ:SERA – Get Free Report) and Alector (NASDAQ:ALEC – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.
Volatility & Risk
Sera Prognostics has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Alector has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.
Earnings & Valuation
This table compares Sera Prognostics and Alector”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sera Prognostics | $80,000.00 | 1,050.36 | -$31.93 million | ($0.67) | -3.18 |
| Alector | $21.05 million | 10.66 | -$142.93 million | ($1.10) | -1.83 |
Sera Prognostics has higher earnings, but lower revenue than Alector. Sera Prognostics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings for Sera Prognostics and Alector, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sera Prognostics | 1 | 0 | 1 | 1 | 2.67 |
| Alector | 2 | 3 | 3 | 0 | 2.12 |
Sera Prognostics presently has a consensus target price of $5.50, indicating a potential upside of 158.22%. Alector has a consensus target price of $3.62, indicating a potential upside of 80.35%. Given Sera Prognostics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Sera Prognostics is more favorable than Alector.
Profitability
This table compares Sera Prognostics and Alector’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sera Prognostics | -47,475.72% | -46.71% | -34.06% |
| Alector | -850.13% | -531.03% | -44.00% |
Institutional and Insider Ownership
54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by company insiders. Comparatively, 8.3% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Sera Prognostics beats Alector on 10 of the 15 factors compared between the two stocks.
About Sera Prognostics
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
About Alector
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.
